Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis


Dazıroğlu M. E., Yıldıran H.

ANNALS OF GASTROENTEROLOGY, cilt.36, sa.2, ss.141-148, 2023 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 36 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.20524/aog.2023.0776
  • Dergi Adı: ANNALS OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.141-148
  • Gazi Üniversitesi Adresli: Evet

Özet

The gut microbiota, which plays an important role in health and disease processes, is affected by many disease processes, such as cirrhosis, and dysbiosis can lead to the development of numerous liver diseases, including complications of cirrhosis. In this disease group, the intestinal microbiota shifts towards dysbiosis for reasons such as endotoxemia, increased intestinal permeability, and decreased bile acid production. Although weak absorbable antibiotics and lactulose are among the treatment strategies in cirrhosis and its most common complication, hepatic encephalopathy (HE), this may not be the most appropriate treatment option for all patients, in view of its sideeffects and high costs. Accordingly, it seems possible that probiotics could be used as an alternative treatment. The use of probiotics in these patient groups has a direct effect on the gut microbiota. Probiotics can also provide treatment with multiple effects through various mechanisms, such as lowering serum ammonia levels, reducing oxidative stress and reducing the intake of other toxins. This review was written to explain the intestinal dysbiosis associated with HE in cirrhotic patients, and the role of probiotics in treatment. Ann Gastroenterol 2023; 36 (X): 1-8